Citius Oncology, INC 8-K filings

Citius Oncology, Inc. has expanded its Board of Directors with the appointment of Jonathan Peri, Ph.D., J.D., an independent director with extensive experience in higher education, financial services, and corporate governance.

Citius Oncology announced a significant 78% quarter-over-quarter increase in new institutional accounts ordering LYMPHIR, alongside strong payer coverage and growing vial orders.

Citius Oncology announced Phase 1 clinical data for LYMPHIR in combination with pembrolizumab in recurrent or refractory gynecologic malignancies, showing durable responses and manageable tolerability.

Citius Oncology reports $5.6 million in six-month net revenue for LYMPHIR and secures $36.5 million in new financing.

Citius Oncology announced a $25 million senior secured term loan facility from Avenue Capital Group and an $11.5 million warrant exercise, totaling $36.5 million to fund LYMPHIR commercialization.

Citius Oncology has been notified by Nasdaq that its common stock has fallen below the minimum $1.00 bid price requirement for continued listing.

Citius Oncology provides a positive commercial update on the U.S. launch of LYMPHIR, highlighting early adoption, broad payer coverage, and expanding clinical development.

Citius Oncology announced positive topline safety and efficacy results from a Phase 1 trial of LYMPHIR in high-risk relapsed or refractory diffuse large B-cell lymphoma patients.

Citius Oncology, Inc. announced its first reported revenue of $3.9 million following the successful U.S. commercial launch of LYMPHIR for CTCL.

Citius Oncology announced the U.S. launch of its cancer immunotherapy LYMPHIR and reported fiscal year 2025 financial results, including strategic financings.

Citius Oncology completed an $18 million concurrent registered direct offering and private placement to fund the commercial launch of its FDA-approved cancer therapy, LYMPHIR.

Citius Oncology announces the U.S. commercial launch of LYMPHIR, an FDA-approved IL-2 receptor-directed fusion protein for relapsed or refractory Stage I-III cutaneous T-cell lymphoma, targeting a $400M+ market.

Citius Oncology, Inc. stockholders approved an amendment to double the shares authorized under its 2024 Omnibus Stock Incentive Plan from 15 million to 30 million.

Citius Oncology, Inc. announced its readiness to commercialize FDA-approved LYMPHIR in Q4 2025 for relapsed or refractory cutaneous T-cell lymphoma, targeting a $400M+ U.S. market.

Citius Oncology, Inc. increased the shares reserved for its 2024 Omnibus Stock Incentive Plan and issued warrants to a financial advisor.

Citius Oncology, Inc. successfully closed a $9.0 million registered direct offering and concurrent private placement to fund its oncology therapies development.

Citius Oncology, Inc. filed a prospectus supplement to update its Form S-1 registration statement following a recent public offering of common stock and warrants.

Citius Oncology, Inc. announced its fiscal third quarter 2025 financial results, reporting an increased net loss while preparing for the commercial launch of its oncology therapy, LYMPHIR, in Q4 2025.

Citius Oncology, a subsidiary of Citius Pharmaceuticals, successfully closed a public offering raising approximately $9.0 million in gross proceeds to advance the commercialization of its FDA-approved oncology therapy, LYMPHIR.

Citius Oncology, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, effectively closing the matter with the exchange.

Citius Oncology, Inc. announced that preparations for the commercial launch of its FDA-approved immunotherapy, LYMPHIR, for relapsed or refractory cutaneous T-cell lymphoma (CTCL) are nearing completion, with a U.S. launch planned for the second half of 2025.

Citius Oncology reports its Q2 2025 financial results, highlighting increased R&D and G&A expenses, a net loss, and the need for additional capital to support operations beyond May 2025.

Citius Oncology has been notified by Nasdaq that its stock price has fallen below the required $1.00 minimum, potentially leading to delisting if compliance isn't regained by October 20, 2025.

Citius Oncology and Eisai have amended their license agreement to establish a payment schedule for outstanding milestone and development costs related to LYMPHIR, following its FDA approval in August 2024.

Citius Oncology announced its fiscal first quarter 2025 financial results, highlighting progress in commercial readiness for LYMPHIR and ongoing strategic evaluations.

Citius Oncology and Citius Pharmaceuticals announce that LYMPHIR has been assigned a unique, permanent J-code by the Centers for Medicare & Medicaid Services, effective April 1, 2025, to streamline billing and reimbursement.

Citius Oncology and Citius Pharmaceuticals announced significant progress in preparations for the commercial launch of LYMPHIR, an innovative immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL), planned for the first half of 2025.

Citius Oncology has retained Jefferies LLC as its exclusive financial advisor to explore strategic alternatives aimed at maximizing shareholder value.

Citius Oncology announced its fiscal year 2024 results, highlighted by FDA approval of LYMPHIR and progress towards its commercial launch.

Citius Oncology reports encouraging preliminary results from a Phase I trial combining LYMPHIR and pembrolizumab, showing a 27% objective response rate and a 33% clinical benefit rate in patients with recurrent solid tumors.